Science China Life Sciences

, Volume 57, Issue 6, pp 586–595

Treatment of osteoarthritis with mesenchymal stem cells

Authors

  • Wen Wang
    • Cellular Biomedicine Group
    • Cellular Biomedicine Group
Open AccessReview Special Topic: Stem Cells and Regenerative Medicine

DOI: 10.1007/s11427-014-4673-7

Cite this article as:
Wang, W. & Cao, W. Sci. China Life Sci. (2014) 57: 586. doi:10.1007/s11427-014-4673-7

Abstract

Osteoarthritis (OA) is one of the most prevalent joint diseases with prominent symptoms affecting the daily life of millions of middle aged and elderly people. Despite this, there are no successful medical interventions that can prevent the progressive destruction of OA joints. The onset of pathological changes in OA is associated with deviant activity of mesenchymal stem cells (MSCs), the multipotent precursors of connective tissue cells that reside in joints. Current therapies for OA have resulted in poor clinical outcomes without repairing the damaged cartilage. Intra-articular delivery of culture-expanded MSCs has opened new avenues of OA treatment. Pre-clinical and clinical trials demonstrated the feasibility, safety, and efficacy of MSC therapy. The Wnt/β-catenin, bone morphogenetic protein 2, Indian hedgehog, and Mitogen-activated protein kinase signaling pathways have been demonstrated to be involved in OA and the mechanism of action of MSC therapies.

Keywords

osteoarthritismesenchymal stem cellsintra-articular delivery
Download to read the full article text

Copyright information

© The Author(s) 2014